| ¿µ¹® | hearing test | ÇÑ±Û | û·Â°Ë»ç |
|---|---|---|---|
| ¼³¸í | ±Í°¡ µé¸®´Â Á¤µµ¸¦ ÃøÁ¤ÇÏ´Â °Ë»ç. û°¢°Ë»ç¶ó°íµµ ÇÑ´Ù. ¼Ò¸®³ª ¸ñ¼Ò¸®°¡ Àß µé¸®´ÂÁöÀÇ ¿©ºÎ µî û°¢ÀÇ ¿¹¹ÎÇÑ Á¤µµ¸¦ ÃøÁ¤ÇÏ´Â ÀÏÀÌ´Ù. °Ë»ç¿¡´Â û·Â°è³ª ¼Ò¸®±Á¼è µîÀÇ ±â±¸¿¡ ÀÇÇØ¼ ¾ò´Â À½¿ø, Áï ¼øÀ½À» »ç¿ëÇϸç, »ç¶÷ÀÇ ¸ñ¼Ò¸®³ª ½Ã°è¼Ò¸® µîµµ À½¿øÀ¸·Î »ç¿ëµÈ´Ù. ¶Ç À½ÆÄ°¡ ÀüÆÄµÇ´Â ¸ÅÁú¿¡ µû¶ó ±âµµ û·Â°Ë»ç¿Í °ñµµ û·Â°Ë»ç·Î ±¸º°µÇ±âµµ ÇÑ´Ù. °Ë»çÀÇ ³»¿ëÀ¸·Î´Â û°¢ÀÇ »óÇÏÀ½°è³ª ÃÖ¼Ò °¡Ã»¹®ÅΰªÀÇ °Ë»ç¸¦ ºñ·ÔÇÏ¿©, ÃæºÐÈ÷ µé¸®´Â ¼Ò¸®¸¦ »ç¿ëÇÏ¿© ±×°ÍÀÌ µé¸®´Â »óŸ¦ Á¶»çÇÏ´Â ¹®Åΰª°Ë»ç(¼Ò¸®ÀÇ Å©±â¿Í »óÅÂÀÇ °Ë»ç, ¼¼±âÀÇ ÆÇº°¿ª°Ë»ç µî) ¿Ü¿¡ À½ÇâÀÚ±ØÀÇ ¹ÝÀÀÀ¸·ÎºÎÅÍ Å¸°¢ÀûÀ¸·Î Á¶»çÇÏ´Â ¹æ¹ýµµ ÀÖÀ¸¸ç, À̰ÍÀº ÁÖ·Î °«³¾Æ±â³ª Á¤½Åº´È¯ÀÚ¿¡ ´ëÇÏ¿© »ç¿ëµÈ´Ù. ÁַΠû·Â°è°¡ »ç¿ëµÇ°í, û·ÂÀº µ¥½Ãº§(dB)·Î Ç¥½ÃµÈ´Ù. Á¤»óÀÎÀº 0dBÀ̰í, ³Ã»ÀÚÀϼö·Ï ±× ¼ö°¡ Ä¿Áö¸ç, 60dBÀÌ»óÀº »ó´çÈ÷ ³Ã»À̰í, 80dB ÀÌ»óÀÌ¸é ±Í¸Ó°Å¸®ÀÌ´Ù. |
||
| ¿µ¹® | Coombs test | ÇÑ±Û | Å©¿òÁî°Ë»ç |
|---|---|---|---|
| ¼³¸í | ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ý. Ç×ü¶õ ƯÁ¤ÇÑ ¹°Áú¿¡ ºÎÂøµÇ¾î ±× ¹°ÁúÀÇ ÀÛ¿ëÀ» ¾ïÁ¦Çϰí, ¶Ç´Â ±× ¹°ÁúÀ» ÆÄ±«ÇÏ´Â °ÍÀ¸·Î B-¸²ÇÁ±¸¶ó´Â ¸é¿ªÀ» ´ã´çÇÏ´Â ¼¼Æ÷¿¡ ÀÇÇØ¼ ¸¸µé¾îÁø´Ù. ÀÌ Å©¿òÁî°Ë»ç¿¡´Â Á÷Á¢Å©¿òÁî°Ë»ç¿Í °£Á¢Å©¿òÁî°Ë»çÀÇ µÎ °¡Áö°¡ Àִµ¥ Á÷Á¢ Å©¿òÁî°Ë»ç´Â ¸ö¼ÓÀÇ ÀûÇ÷±¸¿¡ Á÷Á¢ ºÎÂøµÇ¾î ÀÖ´Â Ç×ü¸¦ °Ë»çÇÏ´Â ¹æ¹ýÀÌ´Ù. äÃëÇÑ Ç÷¾×À» ÀûÇ÷±¸¸¦ ¾ò¾î¼ »ç¶÷ÀÇ Ç×ü¿¡ ´ëÇÑ Ç×ü(»ç¶÷ÀÇ Ç×ü¿¡ ƯÁ¤ÇÏ°Ô ºÎÂøÀÌ µÇ´Â Ç×ü)¸¦ ¹ÝÀÀ½Ã۸é, ¸¸¾à ÀûÇ÷±¸¿¡ ´ëÇÑ Ç×ü°¡ ºÎÂøµÇ¾î ÀÖ´Â ÀûÇ÷±¸¶ó¸é »ç¶÷ÀÇ Ç×ü¿¡ ´ëÇÑ Ç×ü°¡, ÀÛ¿ëÇÏ¿© ħ° ¹ÝÀÀÀÌ ÀϾ°Ô µÇ°í Ç×ü°¡ ºÎÂøµÇ¾î ÀÖÁö ¾Ê´Â ÀûÇ÷±¸ÀÌ¸é ¹ÝÀÀÀÌ ÀϾÁö ¾Ê´Â °ÍÀ» ÀÌ¿ëÇÑ´Ù. °£Á¢Å©¿òÁî°Ë»ç´Â Ç÷Àå¼Ó¿¡ Á¸ÀçÇÏ´Â ÀûÇ÷±¸¿Í ºÎÂøµÇ¾î ÀÖÁö ¾ÊÀº Ç×ü¸¦ ã¾Æ³»´Â ½ÃÇèÀ¸·Î Ç÷ÀåÀ» äÃëÇØ¼ ´Ù¸¥ »ç¶÷ÀÇ ÀûÇ÷±¸¿Í ¹ÝÀÀÀ» ½ÃŰ°í ¿ª½Ã Ç×ü¿¡ ´ëÇÑ Ç×ü¸¦ ¹ÝÀÀ½ÃÄÑ Ä§°¹ÝÀÀÀ» °üÂûÇØ¼ ±× Ç×ü¸¦ ã¾Æ³»´Â ¹æ¹ýÀÌ´Ù. |
||
| ¿µ¹® | tuberculin test | ÇÑ±Û | Æ©º£¸£Ä𸰰˻ç |
|---|---|---|---|
| ¼³¸í | ¸¹Àº ¼·Î ´Ù¸¥ ÇüÅÂÀÇ Æ©º£¸£Ä𸰰ú ´Ù¾çÇÑ Åõ¿©¹æ¹ý¿¡ ÀÇÇÑ ¸ðµç Á¾·ùÀÇ °áÇÙ ÇǺΰ˻ç¹ý. ÇöÀç Ç¥ÁØ ½ÃÇè¹ýÀ¸·Î µÇ¾îÀÖ´Â °¡Àå ½Åºù¼ºÀÖ´Â °Ë»ç·Î´Â PPD¸¦ Çdz»ÁÖ»çÇÏ´Â ¹æ¹ý¸ÁÅä¿ì °Ë»çÀÌ´Ù. Çdz»ÁÖ»çÈÄ 48~72½Ã°£ ÈÄ¿¡ ÁÖ»çºÎÀ§¿¡ Á÷°æ 10mmÀÌ»óÀ¸·Î º¸À̸ç, ¸¸Á®Áö´Â È«¹Ý°ú °æÈ°¡ ³ªÅ¸³ª¸é ¾ç¼ºÀÌ´Ù. ¼ºÀο¡°Ô´Â ÀϹÝÀûÀ¸·Î Áß°£ °µµÀÇ Æ©º£¸£Äð¸°(5Tu)À» »ç¿ëÇϸç, ¾ç¼º¹ÝÀÀÀÌ ³ªÅ¸³ª¸é °áÇÙ±Õ¿¡ ÀÌÀü¿¡ °¨¿°µÇ¾ú°Å³ª ÇöÀç °¨¿°µÇ¾î ÀÖ´Ù´Â È®Á¤Àû Áø´ÜÀÌ µÈ´Ù. À½¼º¹ÝÀÀÀº °áÇÙÀÌ ¾ø°Å³ª, ½ÉÇÑ °áÇÙ°¨¿°¿¡ ÀÇÇÑ ÇǺξ˷¹¸£±â°¡ ÀÖÀ» °æ¿ì, ¶Ç´Â ¸é¿ª¾ïÁ¦¸¦ ³ªÅ¸³»´Â º´, ¿¹¸¦ µé¸é È£ÁöŲº´À̳ª »ç¸£ÄÚÀ̵åÁõ µîÀÌ ÇÕº´µÈ °æ¿ìÀÌ´Ù. |
||
| ¿µ¹® | Papanicolaou smear(test) | ÇÑ±Û | ÆÄÆÄ´ÏÄÝ·Î µµ¸»°Ë»ç |
|---|---|---|---|
| ¼³¸í | ÁÙ¿©¼ ÆËµµ¸»°Ë»ç(Pap smear)À̶ó°í ºÎ¸¥´Ù. ¿©¼ºÀÇ Àڱøñ¾ÏÀÇ ¹ß»ýÀ» ¹Ì¸® ¾Ë¾Æº¸±â À§ÇØ ½ÃÇàÇÏ´Â °Ë»ç¹ýÀ¸·Î ¹Ì±¹¿¡¼´Â ÀÌ ¹æ¹ýÀ¸·Î ÇöÀç Àڱøñ¾Ï¹ß»ý¿¡ ÀÇÇÑ »ç¸Á·üÀ» ÇöÀúÈ÷ ³·Ãß°í ÀÖ´Ù. ¹æ¹ýÀº »êºÎÀΰú¿¡¼ ½ÃÇàÇϸç, ¿©¼ºÀÇ Àڱøñ¿¡¼ ¼¼Æ÷¸¦ °¡Á®´Ù°¡ µµ¸»ÇÏ¿© Çö¹Ì°æÀ¸·Î °Ë»çÇÑ´Ù. ¿äÁîÀ½¿¡ ¿Í¼´Â Àڱøñ»Ó ¾Æ´Ï¶ó È£Èí±â³ª ºñ´¢±â µî ºÐºñ¹°À» µµ¸»ÇÏ¿© ÆÄÆÄ´ÏÄÝ·Î ¿°»öÀ» ÇÏ¿© °Ë»çÇÏ´Â °Íµµ ¿©±â¿¡ Æ÷ÇԵȴÙ. (±×¸² P-3). |
||
| ¿µ¹® | glucose tolerance test | ÇÑ±Û | Æ÷µµ´ç°ßµõ°Ë»ç |
|---|---|---|---|
| ¼³¸í | Æ÷µµ´ç°ßµõ °Ë»ç¶õ ´ç´¢º´ÀÇ Áø´Ü¿¡ »ç¿ëµÇ´Â °Ë»ç·Î ´çÀ» ü³»¿¡ Åõ¿©ÇÏ°í ½Ã°£ º°·Î Ç÷¾×À» äÃëÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ Àç¾î¼ °íÇ÷´ç ¿©ºÎ¸¦ Á¶»çÇÏ´Â °Ë»çÀÌ´Ù. ÁÖ·Î °æ±¸Æ÷µµ´ç°ßµõ°Ë»ç(oral glucose tolerance test)¸¦ ¸¹ÀÌ Çϴµ¥ À̰ÍÀº 10~16½Ã°£ÀÇ ±Ý½Ä ÈÄ¿¡ äÇ÷À» Çѹø Çѵڿ¡ µµ´ç 75gÀ» 250~300mLÀÇ ¹°¿¡ ³ì¿© 5ºÐ¿¡ °ÉÃļ ¸¶½Ã°Ô ÇÏ°í ¸Å½Ã°£ º°·Î äÇ÷À» ÇÏ¿© Ç÷´çÀÇ ³óµµ¸¦ ýũÇÑ´Ù. °øº¹½Ã¿¡ Á¤¸Æ¿¡¼ äÇ÷ÇÏ¿© ÃøÁ¤ÇÑ Ç÷´çÀÌ 140mg/dLÀÌ»óÀ̰ųª Æ÷µµ´ç°ßµõ °Ë»ç 2½Ã°£ÈÄÀÇ Ç÷´çÀÌ 200mg/dLÀÌ»óÀÏ °æ¿ì¿¡´Â ´ç´¢º´À¸·Î Áø´ÜÀ» ÇÑ´Ù. ±×·¯³ª ÀÌ °Ë»ç¸¦ ½Ç½ÃÇÒ °æ¿ì¿¡ ÁÖÀÇÇØ¾ß ÇÒ Á¡Àº °Ë»çÀü 3Àϰ£ ÇÏ·ç¿¡ 150gÀÌ»óÀÇ Åº¼öȹ°À» ¼·ÃëÇØ¾ß ÇÑ´Ù´Â °Í°ú °Ë»çµµÁß¿¡ ¿îµ¿, Èí¿¬ µîÀ» ÇÏÁö ¾Ê¾Æ¾ß ÇÑ´Ù´Â °ÍÀÌ´Ù. |
||
| SRT | sedimentation rate test; simple reaction time; sinus node recovery time; sitting root test; speech r... |
|---|---|
| ST | esotropia; scala tympani; scaphotrapezoid; sclerotherapy; sedimentation time; semitendinosus; sensor... |
| PS test | Pancreozymin-Secretion test = combined secretin-CCK test |
| AAT | Aachen Aphasia Test; academic aptitude test; alanine aminotransferase; alkylating agent therapy; alp... |
| AST | allergy serum transfer; angiotensin sensitivity test; anterior spinothalamic tract; antistreptolysin... |
| haemoglobin H | <haematology> Haemoglobin H is an abnormal version of the protein haemoglobin. The normal haemoglobin is composed of two alpha and two beta polypeptide chains, haemoglobin H is composed of four beta chains. The molecule has a very high affinity to oxygen, but is very inefficient at transporting it. (09 Oct 1997) |
|---|---|
| haemoglobin I | An abnormal Hb with a single a chain substitution, molecular formula a216Lys→Glub2A; a thalassaemia-like syndrome has been found in individuals heterozygous for both Hb I and alpha-thalassaemia genes, with formation of about 70% Hb I. (05 Mar 2000) |
| haemoglobin J | <chemical> A group of abnormal haemoglobins with similar electrophoretic characteristics. They have faster electrophoretic mobility and different amino acid substitutions in either the alpha or beta chains than normal adult haemoglobin. Some of the variants produce haematologic abnormalities, others result in no clinical disorders. Chemical name: Haemoglobin J (12 Dec 1998) |
| haemoglobin JCapetown | An abnormal Hb with a single a chain substitution, molecular formula a292Arg→Glnb2A; heterozygotes have polycythemia because of increased oxygen affinity of this Hb. (05 Mar 2000) |
| haemoglobin Kansas | An abnormal Hb of molecular formula a2Ab2102Asn→Thr; found in association with familial cyanosis due to decreased oxygen affinity of this Hb. (05 Mar 2000) |
| haemoglobin Lepore | A group of abnormal Hb's with normal a chains, but the non-a chains consist of the N-terminal portion of the d chain joined to the C-terminal portion of the b chain, apparently as the result of nonhomologous pairing and crossing over between the genes for b and d chains. The major types are Hb LeporeBoston (identical to Hb LeporeWashington), Hb LeporeHollandia, and Hb LeporeBaltimore, which differ in the region of crossing over (d87-b116, d22-b50, and d50-b86, respectively). Heterozygotes form about 10% Hb Lepore, normal amounts of Hb A2, and moderately increased amounts of Hb F and usually have mild anaemia, microcytosis, and hypochromia; homozygotes form only Hb Lepore and Hb F and have severe anaemia. Compare: haemoglobin Anti-Lepore. (05 Mar 2000) |
| haemoglobin M | <chemical> A group of abnormal haemoglobins in which amino acid substitutions take place in either the alpha or beta chains but near the haem iron. This results in facilitated oxidation of the haemoglobin to yield excess methemoglobin which leads to cyanosis. Chemical name: Haemoglobin M (12 Dec 1998) |
| haemoglobin Portland | A form of embryonic haemoglobin containing the ζ chains of haemoglobin Gower-1 and the g chains of Hb F, thus having the formula ζ2g2; essentially disappears by the third month of pregnancy. Compare: haemoglobin Gower-1, haemoglobin Gower-2. (05 Mar 2000) |
| haemoglobin Rainier | An abnormal Hb of the molecular formula a2Ab2145Tyr→Cys; heterozygotes have polycythemia because of increased oxygen affinity of this Hb. (05 Mar 2000) |
| haemoglobin S | <haematology> Haemoglobin S is an abnormal version of the protein haemoglobin. The sixth amino acid of the normal beta chain, glutamic acid, is replaced by valine with gluconic acid. This mutation causes the red blood cell to take on a sickle shape, and is the cause of the sickle cell trait condition (when the individual is heterozygous for this mutant haemoglobin) and the disease of sickle cell anaemia (when the individual is homozygous for this mutant haemoglobin). (09 Oct 1997) |
| haemoglobin SC disease | <disease, haematology> A rare genetic disease of the haemoglobin. Consists of two abnormal haemoglobins: s and C. Estimated prevalence to be 0.04 to 0.13% in the African American population. Patients are anemic due to the premature breakdown of the blood cells in the spleen. Produces a sickle cell-like syndrome. Jaundice may be seen in some patients. Complications include thromboembolic disease, renal papillary necrosis, aseptic necrosis of the femoral (and humeral) head, increased rates of early spontaneous abortion (in pregnant women with SC disease) and proliferative retinopathy. There is no specific treatment other than supportive care. (27 Sep 1997) |
| haemoglobin, sickle | An abnormal haemoglobin resulting from the substitution of valine for glutamic acid at position 6 of the beta chain of the globin moiety. The heterozygous state results in sickle cell trait, the homozygous in sickle cell anaemia. (12 Dec 1998) |
| haemoglobin Yakima | An abnormal Hb of the molecular formula a2Ab299Asp→His; heterozygotes have polycythemia because of increased oxygen affinity of this Hb. (05 Mar 2000) |
| hereditary persistence of foetal haemoglobin | <haematology> Hereditary persistence of foetal haemoglobin is a genetic condition where adult types of haemoglobin fail to develop and the types of haemoglobin the individual had as a foetus remains present well past the point when they would normally have stopped being produced. (09 Oct 1997) |
| sickle cell haemoglobin | <haematology> Haemoglobin S is an abnormal version of the protein haemoglobin. The sixth amino acid of the normal beta chain, glutamic acid, is replaced by valine with gluconic acid. This mutation causes the red blood cell to take on a sickle shape, and is the cause of the sickle cell trait condition (when the individual is heterozygous for this mutant haemoglobin) and the disease of sickle cell anaemia (when the individual is homozygous for this mutant haemoglobin). (09 Oct 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|